Kornimate/medical-research-clean huggingface dataset:
electrical stimulation for erector spinae plane catheter insertion

Conditions: Postoperative Pain, Acute; Shoulder Pain

Summary: the erector spinae plane (esp) block has been studied for analgesia in shoulder surgery as a phrenic nerve-sparing alternative. however, successful esp catheter placement appears multifactorial, with failure mechanisms including lamination, plane collapse, or catheter overcoiling. electrical stimulation (es) is a common technique used in regional anesthesia to detect possible intraneural placement. es of the erector spinae muscle complex may objectively guide proper interfascial catheter placement and improve local anesthetic spread. the primary goal of this study is to establish if esp catheter placement with the addition of es to ultrasound (us) guidance facilitates accurate catheter placement. this study will further characterize postoperative analgesia and the incidence of brachial plexus stimulation for patients who receive es-assisted esp catheter placement.


Eligibility criteria:
inclusion criteria: * elective total or total reverse shoulder arthroplasty exclusion criteria: * inability to provide consent * history of active opioid use * emergency procedures * shoulder arthroscopy * partial shoulder replacement * shoulder resurfacing * any revision shoulder surgery * any indwelling deep brain stimulator, pacemaker, and/or other neurostimulators

Keywords: erector spinae plane electrical stimulation
exploratory study to assess the efficacy and safety of tc-5214 in the treatment of subjects with palmar hyperhidrosis

Conditions: Palmar Hyperhidrosis

Summary: this is a pilot exploratory study to evaluate the safety and efficacy of tc-5214 in subjects with palmar hyperhidrosis.


Eligibility criteria:
inclusion criteria: * subject has a clinical diagnosis of primary hyperhidrosis of the palms * subject is currently drug-naïve for hyperhidrosis medications * females must be post-menopausal, surgically sterile, or use an effective method of birth control. exclusion criteria: * subject is pregnant, lactating, is planning to become pregnant during the study, or is less than one year postpartum. * subject is a smoker within one year prior to visit 1/screening. * subject has known history of secondary hyperhidrosis. * subject has existence of neurological, psychiatric, endocrine, or other disease that can cause secondary hyperhidrosis or affect sweating. * subject has known history of sjögren's syndrome or sicca syndrome. * subject has used any of the following hyperhidrosis medications or therapies within the specified timeframe: 1. iontophoresis to the palms within four weeks prior to baseline visit; 2. botulinum toxin to the palms within one year prior to baseline visit; 3. prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands); 4. prior medical device treatment to the palms (approved or investigational); 5. any treatments for hyperhidrosis within four weeks prior to baseline visit. * subject is currently enrolled in an investigational drug or device study. * subject has previously participated in a clinical study of dexmecamylamine or tc-5214. * subject has used an investigational drug or investigational device treatment within 30 days prior to baseline. * subject has a history of sensitivity to any of the ingredients in the study drugs.

Keywords: sweaty hands
effect of dapagliflozin on lv remodeling post ami

Conditions: Myocardial Infarction

Summary: the overall hypothesis of the study is that dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction.

in patients with heart failure, with or without diabetes, sglt2i have shown to decrease remodeling. however, this has not been tested in patients following an acute myocardial infarction. acute myocardial infarction is serious condition with increasing incidence across the world. following treatment, a reasonable amount of patients develop remodeling of the left ventricle, which is associated with worse prognosis. this occurs despite patients are treated with gdmt. dapagliflozin is an sglt2i with biological plausibility to decrease left ventricular remodeling following acute myocardial infarction. in the present study, researchers will test the hypothesis that dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction (less than 7 days). this will be a randomized, single-blind, placebo controlled trial. the primary endpoint will be the change in end-diastolic and end-systolic left ventricular volumes from baseline to the end of the intervention (6 months). we will include patients with acute myocardial infarction who have been treated with primary pci.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction treated within the 24 hours of beginning of symptoms * signed informed consent * sbp \> 90 mmhg * age \>= 18 years exclusion criteria: * glomerular filtration rate \< 30 ml/min/1.73 m2. * pregnant or lactating woman * cancer or life-threatening condition * use of continuous parental inotropic agents * psychiatric disease incompatible with being in study. * any contraindication to mri procedures. * any other medical or physical condition considered to be inappropriate by a study physician * scheduled for a pci or cabg within the next 6 months * hemodynamic unstability * currently on any sglt2i * one or more episodes of severe hypoglicemia * acute urinary or genital infection
study evaluating the effect of moving virtual scenes on postural balance in a stroke rehabilitation setting

Conditions: Stroke Rehabilitation; Postural Equilibrium

Summary: this is an interventional, prospective, randomized, monocentric study designed to develop medical knowledge. virtual reality is increasingly used in rehabilitation. the aim of virtual reality is to investigate motor interactions in a fictitious, configurable environment, in order to train specific functions and transpose improvements into everyday life. the main objective of this study is to investigate the influence of different moving virtual scenes on the general spatiotemporal parameters of pressure centers, in a sub-acute stroke rehabilitation context. this would help health professionals to assess the most suitable vr exercise in function of patient's difficulties. during this study, patient movements while viewing 8 different virtual reality scenes will be recorded using a motion platform during a single session.


Eligibility criteria:
inclusion criteria: * age: over 18 * adult patient in rehabilitation stay (day or full hospitalization) following a first stroke less than 6 months old. * one of the rehabilitation objectives is to improve balance * ability to understand exercise instructions * ability to stand for at least one minute with eyes closed, safely and without technical assistance * ability to walk at least with technical assistance and/or supervision * patient having given their informed consent * patient affiliated to a social security scheme non -inclusion criteria : * patients with epilepsy, controlled or not * patients undergoing rehabilitation following a stroke in the posterior fossa * known history of vestibular or cerebellar balance disorders * patients with orthopedic or traumatological impairment preventing stabilometric measurement on a force platform without footwear * patient under legal protection measure * severe phasic disorders that may prevent the expression of the will to stop viewing virtual scenes or to respond to numerical scales * pregnant or breastfeeding woman * known history of motion sickness * patient participating or having participated in the balance rehabilitation program with virtual reality within the rehabilitation center during their stay exclusion criteria : * cyberkinetosis represented by a score greater than or equal to 15 on the fast motion sickness scale * poor tolerance for wearing a virtual reality headset * significant visual impairment preventing the perception of the stimulus visual
surgery alone versus neoadjuvant treatment followed by surgery for mri-defined t3 mid-low rectal cancer

Conditions: Rectal Cancer

Summary: neoadjuvant treatments (ncrt) are becoming the standard treatment for patients with stage ii or stage iii mid-low rectal cancer. in fact, with the introduction of total mesorectal excision, the local recurrence has been reduced significantly. recently few studies have shown that surgery alone is enough for patients with t3 rectal cancer. these issues raised the question of whether ncrt is needed for all t3 rectal cancer patients. therefore, this study was designed to compare the long-term oncological outcomes between surgery and surgery following ncrt among patients with mri-defined t3, clear mrf mid-low rectal cancer.


Eligibility criteria:
inclusion criteria: 1. eighteen- to eighty-year-old patients. 2. t3 rectal cancer with clear mesorectal fascia (mrf), 3. within 12 cm from the anal verge at initial diagnosis by magnetic resonance imaging (mri) exclusion criteria: 1. emergency surgery due to bleeding, perforation, and bowel obstruction, 2. recurrent rectal cancer, 3. inflammatory bowel disease, 4. stage iv.
extended-release melatonin in patients with rapid eye movement sleep behavior disorder

Conditions: Rapid Eye Movement Sleep Behavior Disorder; Parkinson Disease

Summary: the purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with parkinson disease and rapid eye movement sleep behavior disorder.

enrolled patients with parkinson disease and previously diagnosed rapid eye movement sleep behavior disorder, who are being treated at mayo clinic in florida, will be randomized to receive either immediate-release melatonin or extended-release melatonin and then will be crossed over to receive the opposite intervention. the study will consist of two treatment periods of 4 weeks separated by a washout period of 2 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease and rapid eye movement sleep behavior disorder. * patient registered to parkinson's disease database of mayo clinic florida. exclusion criteria: * patients who are using other sleep aids or medications (clonazepam). * patients who are not willing to undertake 1 week of washout period. * patients who do not sign a consent for research.
montmorency cherry juice and uric acid metabolism

Conditions: Inflammation

Summary: cherries have been show to possess the ability to reduce uric acid concentrations and inflammation. tart montmorency cherries possess a higher concentration of the plant compounds than other cherries and hence makes the expectation possible that montmorency cherries will lower uric acid and inflammation.

plasma and urinary uric acid concentration, plasma phytochemical content and inflammatory biomarkers will be measured in order to elucidate the effects of an acute dose of tart cherry juice on indices related to the condition of gout. participants will be required to attend the laboratory at a range of time points over two periods of 96 hours, separated by a 7 day washout period, to provide blood samples. in order to provide a baseline sample, participants will attend the laboratory in the morning following an overnight fast and voiding of any urine. following this participants will be given 30mls (30 mls provides 323 mg/380 µmol of anthocyanins) of tart cherry juice or placebo, diluted with 60 mls of water to consume within 10 minutes. participants will be required to consume identical dosages of the supplement immediately prior to evening meals and breakfasts (or same time each morning following blood sampling if non-breakfast eater) over the next 96 hours. further blood and urine samples will be collected at 1, 2, 3, 5, 8, 24, 26, 48, 50, 72, 74 and 96 hours and will require participants to return to the laboratory at each of these time points. following the first period of supplementation participants will complete a 7 day washout period in which they will not be required to attend the laboratory. following the washout period they will repeat the supplementation period consuming the supplement they did not receive during the first period.

Eligibility criteria:
inclusion criteria: * apparently healthy males/females between the ages of 18-40 years exclusion criteria: * underlying clinical pathology

Keywords: montmorency tart cherries inflammation uric acid
assessment of circulating tumor cells and micrornas in patients with metastatic non-cutaneous melanoma

Conditions: Melanoma Neoplasms

Summary: the study aims to implement new approaches for the identification of circulating tumor cells and circulating micrornas, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). it also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.

here we propose a study to identify a technique for the isolation of circulating tumor cells (ctcs) from blood samples of patients with diagnosis of metastatic melanoma (uveal, mucosal, from primary unknown) to identify a potential role of ctcs and to study the role for circulating micrornas (mirnas) in the management of metastatic um, mm and mup.

Eligibility criteria:
inclusion criteria: * diagnosis of um, mm or mup * diagnosis of metastatic disease * age ≥ 18 years, at the time of the tissue collection exclusion criteria: * personal medical history of concomitant other cancer

Keywords: uveal melanoma mucosal melanoma melanoma primary unknown
efficacy and safety of continuous infusion of terlipressin vs bolus terlipressin in aclf patients with acute esophageal variceal bleed

Conditions: Acute on Chronic Liver Failure

Summary: acute portal hypertension, as measured by rapid rise in hepatic venous pressure gradient (hvpg) can lead to further dreaded complications, including acute variceal bleeding (avb) avb: 6-week mortality rates of around 15-20% in patients with chronic liver disease without aclf.the overall prevalence of ugh in cirrhotic patients with ad was 34.4% and 35.7% in patients with aclf.avb is a well-recognized precipitant leading to the occurrence and development of aclf. avb is a well-recognized precipitant leading to the occurrence and development of aclf. medical therapy for esophageal variceal bleeding (evb) aims to reduce the splanchnic blood flow and portal pressure. the most common vasoactive agents include terlipressin, vasopressin, somatostatin, and octreotide.

aim and objective - to assess the safety and efficacy of continuous terlipressin vs. bolus terlipressin in the management of acute esophageal variceal bleeding in aclf. study population: adult patients (age ≥ 18 years) diagnosed with aclf presenting with upper gi bleeding due to esophageal varices study design: pilot study study period: 1 year sample size: 60 intervention: group i- intravenous terlipressin (administered as a continuous infusion at 4 mg/24 hours). after 12 hours, if the hepatic venous pressure gradient (hvpg) does not show a reduction of less than 10%, increase the dose to 6 mg/24 hours. group ii- intravenous terlipressin (2 mg initially every 4 hourly for 2 days and then 1 mg every 4 hrs) monitoring and assessment: all patients would undergo vital and baseline parameter screening before randomization. based on randomization they will receive either steroid or plasma exchange followed by steroid adverse effects: acute diarrhea, chest pain, arterial hypertension, cardiac arrhythmias, acute abdomen stopping rule: chest pain, alteration of ecg, cyanosis, bradycardia, severe allergic rashes

Eligibility criteria:
inclusion criteria: 1. adult patients (age ≥ 18 years) diagnosed with aclf presenting with due to esophageal varices bleeding. exclusion criteria: 1. age \< 18 years 2. history of coronary heart disease or ventricular arrhythmia, 3. stroke or transient ischemic attack, 4. bronchial asthma, 5. epilepsy, 6. pregnancy, 7. rebleeding. 8. hcc 9. gastric variceal bleed
the anchor study: digitally delivered intervention for reducing problematic substance use

Conditions: Alcohol Use Disorder (AUD); Substance Use Disorders

Summary: this study aims to validate w-suds as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder program (w-suds) to reduce substance use relative to a psychoeducation control condition, which has no cognitive behavioral therapy and the content is not delivered through a conversational user interface.

phase ii will evaluate the efficacy of w-suds in a large scale rct relative to a psychoeducation control condition. primary outcomes will be measures of the quantity and frequency of substance use including number of substance use occasions, heavy drinking days (if applicable) and percent reduction in substance use occasions. additionally, phase ii will evaluate whether w-suds results in a greater reduction in substance-related problems compared to a psychoeducation control group and explore if engagement with w-suds, relative to psychoeducation control, 1. improves symptoms of depression and anxiety; 2. improves work productivity (i.e. reduce presenteeism/absenteeism); 3. reduces cravings; 4. improves situational confidence to resist substance use.

Eligibility criteria:
inclusion criteria: 1. have a smartphone 2. endorse a substance use concern 3. be between 18 and 65 years of age 4. be available and committed to engage with the woebot app 5. be literate in english. (this is required for inclusion because all materials will be in english). exclusion criteria: 1. pregnancy (as w-suds will not be specifically developed to address the unique needs of this population) 2. suicide attempt within the past year (12 months) 3. symptoms of severe drug/alcohol history: history of delirium tremens; experiencing hypertension, drenching sweats, seizures or confusion after stopping alcohol or drugs; liver trouble (cirrhosis or hepatitis); convulsions or gi bleeding due to drug/alcohol use 4. opioid overdose within the past year (12 months) 5. opioid misuse without medication-assisted treatment 6. not residing in the u.s. 7. previous woebot use

Keywords: alcohol use disorder substance use disorder aud sud aud treatment sud treatment smartphone application digital therapeutic alcohol use disorder treatment substance use disorder treatment
oral ahr antagonist in combination with nivolumab in patients with pd-1 resistant metastatic or recurrent head and neck cancer

Conditions: Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer; Head Cancer; Neck Cancer; Head Cancer Neck; Neck Carcinoma

Summary: this is a phase 1b study in adult patients diagnosed with resistant or recurrent head and neck squamous cell carcinoma (hnscc) designed to assess the safety and tolerability of ik-175 in combination with nivolumab. disease response, pharmacokinetics (pk), pharmacodynamics, and response biomarkers will also be assessed.

this is an open-label, multicenter, phase 1b dose-expansion study to evaluate the safety, tolerability, preliminary antitumor activity, pk, and pharmacodynamics of 2 dose levels of ik-175, administered po in combination with nivolumab, in patients with primary pd-1-resistant metastatic or locally incurable, recurrent hnscc for which standard therapy is no longer effective or is intolerable.

Eligibility criteria:
key inclusion criteria: * subject has an eastern cooperative oncology group (ecog) performance status of 0 to 2. * subject has a histologically confirmed metastatic or locally incurable, recurrent hnscc that has progressed within 12 weeks of initiation of pd-1 inhibitor agent, whether it was administered alone or in combination with chemotherapy. * tumors must express pd-l1 with a minimum cps ≥ 1. * subjects can be enrolled regardless of their tumor's expression of human papillomavirus (hpv). * subjects are required to have received prior treatment with a platinum-based chemotherapy in the recurrent or metastatic disease setting, unless medically contraindicated. * subject has at least 1 measurable lesion per recist v1.1. key exclusion criteria: * subject has untreated or symptomatic central nervous system (cns) tumors or brain metastases. * subject must have recovered to ≤ grade 1 from clinically significant aes related to prior therapy (eg, myelosuppression or renal or hepatic dysfunction.) * subject has received prior treatment with an ahr inhibitor. * subject has a medical condition that limits oral administration or impairment of gastrointestinal function that is expected to significantly reduce the absorption of ik-175. * uncontrolled or life-threatening symptomatic concomitant disease. * clinically significant cardiovascular disease as defined in the protocol. * subject is on a medication that is a sensitive substrate of cyp2c8, 2c9, 2c19, or 3a4 that cannot be substituted. * females who are pregnant or breastfeeding. other inclusion/exclusion criteria are listed in the protocol.

Keywords: ik-175 ahr antagonist ahr inhibitor aryl hydrocarbon receptor antagonist immunooncology ahri aryl hydrocarbon receptor inhibitor antagonist inhibitor anti-pd1 apd1 nivolumab checkpoint inhibitor cpi combination therapy